Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Department of Research and development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands.
Int J Cancer. 2023 Apr 1;152(7):1360-1369. doi: 10.1002/ijc.34347. Epub 2022 Nov 30.
We studied the prognostic value of primary tumor sidedness in metastatic colorectal cancer over time and across treatment lines. Population data on synchronous metastatic colorectal cancer patients were extracted from the Netherlands Cancer Registry and SEER database. Pubmed, EMBASE and Cochrane library were searched for prospective studies on metastatic colorectal cancer to conduct a meta-analysis. Inclusion criteria consisted of metastatic disease, systemic treatment with palliative intent and specification of primary tumor location. Data were pooled using a random-effects model. For the population-based data, multivariable Cox models were constructed. The Grambsch-Therneau test was conducted to evaluate the potential time-varying nature of sidedness. Meta-regression incorporating treatment-line as variable was conducted to test the pre-specified hypothesis that the prognostic value of sidedness varies over time. Analysis of 12 885 and 16 160 synchronous metastatic colorectal cancer patients registered in the Netherlands Cancer Registry and SEER database, respectively, indicated a time-varying prognostic value of sidedness (P < .01). Thirty-one studies were selected for the meta-analysis (9558 patients for overall survival analysis). Pooled univariable hazard ratio for overall survival was 0.71 (95% CI: 0.65-0.76) in 1st-line, 0.76 (0.54-1.06) in 2nd-line and 1.01 (0.86-1.19) in 3rd-line studies. Hazard ratios were significantly influenced by treatment line (P = .035). The prognostic value of sidedness of the primary tumor in metastatic colorectal cancer patients treated with palliative systemic therapy decreases over time since diagnosis, suggesting that sidedness may not be a useful stratification factor in late-line trials. This decrease in prognostic value should be taken into account when providing prognostic information to patients.
我们研究了原发肿瘤侧别在转移性结直肠癌中的预后价值,以及它随时间和治疗线数的变化情况。从荷兰癌症登记处和 SEER 数据库中提取了同步转移性结直肠癌患者的人群数据。在 PubMed、EMBASE 和 Cochrane 图书馆中搜索了转移性结直肠癌的前瞻性研究,以进行荟萃分析。纳入标准包括转移性疾病、姑息性全身治疗和原发肿瘤位置的具体说明。使用随机效应模型对数据进行汇总。对于基于人群的数据,构建了多变量 Cox 模型。使用 Grambsch-Therneau 检验评估侧别潜在的时变性质。进行了包含治疗线数的元回归分析,以检验侧别预后价值随时间变化的预设假设。对荷兰癌症登记处和 SEER 数据库中分别登记的 12885 例和 16160 例同步转移性结直肠癌患者进行分析,结果表明侧别具有随时间变化的预后价值(P<0.01)。选择了 31 项研究进行荟萃分析(整体生存分析 9558 例患者)。整体生存的合并单变量危险比为一线治疗时 0.71(95%CI:0.65-0.76),二线治疗时 0.76(0.54-1.06),三线治疗时 1.01(0.86-1.19)。危险比受到治疗线数的显著影响(P=0.035)。接受姑息性全身治疗的转移性结直肠癌患者的原发肿瘤侧别预后价值随诊断后时间的推移而降低,这表明在晚期试验中,侧别可能不是一个有用的分层因素。在向患者提供预后信息时,应考虑到这种预后价值的降低。